Scholarlink

<p>[18F]-Flurpiridaz is an emerging radiopharmaceutical with significant potential to enhance myocardial perfusion imaging. With a myocardial extraction fraction comparable to [15O]-H₂O, Flurpiridaz offers superior image quality, higher diagnostic accuracy, and reduced radiation exposure compared to traditional SPECT tracers. Unlike short half-life PET tracers, Flurpiridaz does not require an on-site cyclotron, making it more accessible for clinical use. Its ability to accurately quantify myocardial blood flow and coronary flow reserve could improve ischemia detection and patient management. However, challenges remain regarding regulatory approval, economic feasibility, and infrastructure adaptation, particularly in Italy, where SPECT remains dominant. Despite these hurdles, Flurpiridaz represents a significant advancement in nuclear cardiology, with the potential to improve diagnostic precision, guide revascularization decisions, and optimize personalized treatment strategies for coronary artery disease. [18F]-Flurpiridaz is an emerging radiopharmaceutical with significant potential to enhance myocardial perfusion imaging. With a myocardial extraction fraction comparable to [15O]-H₂O, Flurpiridaz offers superior image quality, higher diagnostic accuracy, and reduced radiation exposure compared to traditional SPECT tracers. Unlike short half-life PET tracers, Flurpiridaz does not require an on-site cyclotron, making it more accessible for clinical use. Its ability to accurately quantify myocardial blood flow and coronary flow reserve could improve ischemia detection and patient management. However, challenges remain regarding regulatory approval, economic feasibility, and infrastructure adaptation, particularly in Italy, where SPECT remains dominant. Despite these hurdles, Flurpiridaz represents a significant advancement in nuclear cardiology, with the potential to improve diagnostic precision, guide revascularization decisions, and optimize personalized treatment strategies for coronary artery disease.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Flurpiridaz in Italy: a new era for cardiac imaging? Impact and future perspectives in nuclear medicine

  • 期刊论文

  • 发表日期：

    2025年6月13日

查看全文
  • D. Genovesi,
  • A. Giorgetti,
  • R. Assante,
  • W. Acampa,
  • R. Sciagrà,
  • E. Milan,
  • C. Marcassa,
  • R. Giubbini

摘要

[18F]-Flurpiridaz is an emerging radiopharmaceutical with significant potential to enhance myocardial perfusion imaging. With a myocardial extraction fraction comparable to [15O]-H₂O, Flurpiridaz offers superior image quality, higher diagnostic accuracy, and reduced radiation exposure compared to traditional SPECT tracers. Unlike short half-life PET tracers, Flurpiridaz does not require an on-site cyclotron, making it more accessible for clinical use. Its ability to accurately quantify myocardial blood flow and coronary flow reserve could improve ischemia detection and patient management. However, challenges remain regarding regulatory approval, economic feasibility, and infrastructure adaptation, particularly in Italy, where SPECT remains dominant. Despite these hurdles, Flurpiridaz represents a significant advancement in nuclear cardiology, with the potential to improve diagnostic precision, guide revascularization decisions, and optimize personalized treatment strategies for coronary artery disease. [18F]-Flurpiridaz is an emerging radiopharmaceutical with significant potential to enhance myocardial perfusion imaging. With a myocardial extraction fraction comparable to [15O]-H₂O, Flurpiridaz offers superior image quality, higher diagnostic accuracy, and reduced radiation exposure compared to traditional SPECT tracers. Unlike short half-life PET tracers, Flurpiridaz does not require an on-site cyclotron, making it more accessible for clinical use. Its ability to accurately quantify myocardial blood flow and coronary flow reserve could improve ischemia detection and patient management. However, challenges remain regarding regulatory approval, economic feasibility, and infrastructure adaptation, particularly in Italy, where SPECT remains dominant. Despite these hurdles, Flurpiridaz represents a significant advancement in nuclear cardiology, with the potential to improve diagnostic precision, guide revascularization decisions, and optimize personalized treatment strategies for coronary artery disease.